Rules-Based Medicine Newswire (Page 2)

Rules-Based Medicine Newswire (Page 2)

Comprehensive Real-Time News Feed for Rules-Based Medicine. (Page 2)

Results 21 - 40 of 277 in Rules-Based Medicine

  1. Trader's Buzzers: FireEye, Inc.Read the original story

    Feb 21, 2017 | The Oak Ridge Observer

    The stock has a market cap of 47.26 Billion. The company's outstanding shares are 358.24 Million.

    Comment?

  2. Dragon Ball Xenoverse 2 DLC and free updates next weekRead the original story w/Photo

    Feb 21, 2017 | The Oak Ridge Observer

    Recently, a YouTube user named Burst-ZG shared some hints about the possible release date of the " Dragon Ball Xenoverse 2 " DLC Pack update . On the other hand, the paid " Dragon Ball Xenoverse 2 " DLC will be bringing in new playable characters from the "Dragon Ball Super" anime as previously reported by MStars News.

    Comment?

  3. Traders Watch-list Stock: ACADIA Pharmaceuticals Inc.Read the original story

    Feb 21, 2017 | The Oak Ridge Observer

    US based company, Acadia Healthcare Company, Inc.'s 's latest closing price distance was -9.35% from the average-price of 200 days while it maintained a distance from the 50 Day Moving Average at 14.84% and 8.97% compared with the 20 Day Moving Average. The stock as of last trading session moved 130.79% up from its 52 week low and was -7.55% behind its 52 week high.

    Comment?

  4. Sell-Side Analyst's Predictions: Myriad Genetics, Inc.Read the original story

    Feb 21, 2017 | The Oak Ridge Observer

    Shares of Service Corporation International declined -0.10% to $31.32. The most recent upgrade was reported by Ladenburg Thalmann on Feb 08, 2017, with a rating change from Sell to Neutral.

    Comment?

  5. Pacad Investment Ltd. Invests $558,000 in Myriad Genetics, Inc.Read the original story w/Photo

    Feb 21, 2017 | Daily Political

    Pacad Investment Ltd. bought a new stake in Myriad Genetics, Inc. during the fourth quarter, Holdings Channel reports. The firm bought 33,500 shares of the company's stock, valued at approximately $558,000.

    Comment?

  6. GSA Capital Partners LLP Has $2,513,000 Position in Myriad Genetics, Inc.Read the original story w/Photo

    Feb 20, 2017 | Daily Political

    GSA Capital Partners LLP lowered its stake in Myriad Genetics, Inc. by 0.9% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 150,737 shares of the company's stock after selling 1,302 shares during the period.

    Comment?

  7. Myriad's BRACAnalysis CDx Test Successfully Identified...Read the original story

    Feb 17, 2017 | PressReleasePoint

    Myriad Genetics , Inc. , a leader in molecular diagnostics and personalized medicine, today announced new findings from the OlympiAD study that show its BRACAnalysis CDxA test successfully identified patients with HER2-negative metastatic breast cancer who have BRCA mutations and who had improved response with Lynparza , AstraZeneca's PARP inhibitor. The high level results - announced earlier today from AstraZeneca - are the first reported clinical data from the OlympiAD study , which assessed the efficacy and safety of olaparib monotherapy versus physicians' choice of chemotherapy in the treatment of metastatic breast cancer.

    Comment?

  8. Myriad's Prolaris Test Significantly Improves the Risk...Read the original story

    Feb 17, 2017 | PressReleasePoint

    Myriad Genetics, Inc. , a global leader in personalized medicine, today announced new data demonstrating the utility of the ProlarisA test to more accurately classify mortality risk and guide the management of newly diagnosed men with prostate cancer. The data are being presented at the 2017 Genitourinary Cancers Symposium meeting in Orlando, Fla.

    Comment?

  9. Myriad Genetics' (MYGN) Hold Rating Reiterated at Jefferies Group LLCRead the original story w/Photo

    Feb 13, 2017 | IntersportsWire

    A number of other analysts have also weighed in on MYGN. Zacks Investment Research lowered shares of Myriad Genetics from a hold rating to a sell rating in a research note on Tuesday, October 25th.

    Comment?

  10. Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad GeneticsRead the original story w/Photo

    Feb 13, 2017 | TheStreet.com

    Shares of Sage Therapeutics were up 8.6% ahead of the opening bell on Monday, trading at $51.50. The Cambridge, Mass.

    Comment?

  11. Brokerages Set Myriad Genetics, Inc. (MYGN) PT at $28.00Read the original story w/Photo

    Feb 12, 2017 | IntersportsWire

    Shares of Myriad Genetics, Inc. have been assigned a consensus rating of "Hold" from the sixteen brokerages that are covering the firm. Four equities research analysts have rated the stock with a sell recommendation, nine have issued a hold recommendation and one has given a buy recommendation to the company.

    Comment?

  12. FY2017 EPS Estimates for Myriad Genetics, Inc. Lifted by GabelliRead the original story w/Photo

    Feb 12, 2017 | IntersportsWire

    Myriad Genetics, Inc. - Investment analysts at Gabelli boosted their FY2017 EPS estimates for Myriad Genetics in a research note issued to investors on Wednesday. Gabelli analyst S. Wojda now anticipates that the brokerage will earn $1.05 per share for the year, up from their prior estimate of $1.00.

    Comment?

  13. Q3 2017 Earnings Estimate for Myriad Genetics, Inc. Issued By Jefferies GroupRead the original story w/Photo

    Feb 12, 2017 | Daily Political

    Myriad Genetics, Inc. - Stock analysts at Jefferies Group lowered their Q3 2017 earnings estimates for shares of Myriad Genetics in a report issued on Wednesday. Jefferies Group analyst B. Couillard now anticipates that the brokerage will post earnings of $0.24 per share for the quarter, down from their previous forecast of $0.28.

    Comment?

  14. Clinton Group Inc. Has $948,000 Stake in Myriad Genetics, Inc.Read the original story w/Photo

    Feb 11, 2017 | Daily Political

    Clinton Group Inc. decreased its stake in Myriad Genetics, Inc. by 73.9% during the third quarter, according to its most recent filing with the SEC. The fund owned 46,045 shares of the company's stock after selling 130,158 shares during the period.

    Comment?

  15. Myriad Genetics, Inc. (MYGN) to Post FY2021 Earnings of $2.00 Per Share, Gabelli ForecastsRead the original story w/Photo

    Feb 10, 2017 | Daily Political

    Myriad Genetics, Inc. - Research analysts at Gabelli issued their FY2021 EPS estimates for shares of Myriad Genetics in a note issued to investors on Wednesday. Gabelli analyst S. Wojda anticipates that the firm will post earnings per share of $2.00 for the year.

    Comment?

  16. Myriad Genetics, Inc. to Post Q4 2017 Earnings of $0.29 Per Share, Jefferies Group ForecastsRead the original story w/Photo

    Feb 10, 2017 | IntersportsWire

    Myriad Genetics, Inc. - Analysts at Jefferies Group raised their Q4 2017 EPS estimates for shares of Myriad Genetics in a research note issued to investors on Wednesday. Jefferies Group analyst B. Couillard now expects that the brokerage will earn $0.29 per share for the quarter, up from their previous forecast of $0.28.

    Comment?

  17. 1,108,720 Shares in Myriad Genetics, Inc. (MYGN) Acquired by Russell Investments Group Ltd.Read the original story w/Photo

    Feb 10, 2017 | IntersportsWire

    Russell Investments Group Ltd. purchased a new stake in shares of Myriad Genetics, Inc. during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 1,108,720 shares of the company's stock, valued at approximately $18,571,000.

    Comment?

  18. FY2017 Earnings Estimate for Myriad Genetics, Inc. (MYGN) Issued By GabelliRead the original story w/Photo

    Feb 10, 2017 | AmericanBankingNews.com

    Myriad Genetics, Inc. - Analysts at Gabelli raised their FY2017 earnings per share estimates for shares of Myriad Genetics in a research note issued to investors on Wednesday. Gabelli analyst S. Wojda now expects that the brokerage will post earnings per share of $1.05 for the year, up from their prior forecast of $1.00.

    Comment?

  19. Q3 2017 EPS Estimates for Myriad Genetics, Inc. (MYGN) Reduced by Jefferies GroupRead the original story w/Photo

    Feb 10, 2017 | IntersportsWire

    Myriad Genetics, Inc. - Jefferies Group cut their Q3 2017 earnings per share estimates for shares of Myriad Genetics in a report issued on Wednesday. Jefferies Group analyst B. Couillard now anticipates that the firm will post earnings per share of $0.24 for the quarter, down from their previous forecast of $0.28.

    Comment?

  20. Gabelli Weighs in on Myriad Genetics, Inc.'s FY2021 EarningsRead the original story w/Photo

    Feb 9, 2017 | AmericanBankingNews.com

    Myriad Genetics, Inc. - Equities researchers at Gabelli issued their FY2021 EPS estimates for shares of Myriad Genetics in a research report issued to clients and investors on Wednesday. Gabelli analyst S. Wojda anticipates that the firm will earn $2.00 per share for the year.

    Comment?